Eradivir Doses First Influenza Patient With EV25 in Bangladesh Study

Eradivir, Inc., a clinical-stage biotech company developing antibody-recruiting small molecules to treat disease, today ...

Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement

TTI-109 delivered TTI-101-equivalent exposure with improved tolerability and meaningful reductions in disease-relevant STAT3-driven immune cell ...
Investorideas.com

Tvardi Therapeutics (Nasdaq: TVRD) Soars on Positive Phase 1 Results for Next-Gen STAT3 Inhibitor TTI-109

Tvardi Therapeutics (Nasdaq: TVRD) shares surge after Phase 1 results show TTI-109 matched TTI-101's exposure with better tolerability and clear STAT3 target engagement.

Alpha Genesis, Inc.: Alpha Genesis Adds Rodent Studies, Creating an Integrated Rodent-to-Primate Preclinical Platform

New capability lets sponsors run programs from early rodent proof-of-concept through advanced nonhuman-primate translational studies with a single AAALAC-accredited, USDA-licensed partner. YEMASSEE, S ...

HKeyBio Launches NHP Fast-Tox Program for Accelerating Non-GLP NHP Safety Risk Screening

NHP Fast-Tox follows HKeyBio's NHP Fast-PoC Program and extends the company's rapid NHP evaluation framework from early pharmacodynamic proof-of-concept studies to early safety risk assessment.
Rutland Herald

Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors

(Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the U.S. Food and Drug Administration (FDA or the Agency) ...
Pharmabiz

Viking Therapeutics starts Phase 1 study on novel weight loss drug in healthy adults

Viking Therapeutics starts Phase 1 study on novel weight loss drug in healthy adults: San Diego Thursday, June 25, 2026, 18:00 Hrs [IST] Viking Therapeutics, Inc., a clinical-stag ...
News-Medical.Net

FluoGuide announces positive results from Phase 2 oral head and neck cancer trial

FluoGuide A/S, a biotech company maximizing surgical outcomes in oncology by lighting up cancer, today announced positive results from the first part of its ongoing FG001-CT-005 Phase 2 trial ...
The Manila Times

Insilico Initiates Phase III Clinical Trial for Rentosertib, Its AI-Empowered TNIK Inhibitor for Idiopathic Pulmonary Fibrosis

Potentially first-in-class oral TNIK inhibitor advances into late-stage development after milestones marked by vital peer-reviewed papers: the discovery-to-clinic journey in Nature Biotechnology, and ...
Pharmaceutical Technology

Coya Therapeutics CEO on ALS urgency and fast-tracking COYA 302 for patient impact

As CEO of Coya Therapeutics, Dr Arun Swaminathan is steering the company’s lead programme, COYA 302, an immune-modulating combination designed to restore regulatory T-cell function and dampen ...

Viking Therapeutics, Inc.: Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults

Single ascending dose study evaluating safety, tolerability, and pharmacokinetics of VK3019 Potential to further expand Viking's treatment options for weight loss ...

GRI Bio Highlights Promising Phase 2a IPF Data, Outlook

GRI Bio ( (GRI)) has issued an announcement. On May 14, 2026, GRI Bio reported first-quarter 2026 results and new Phase 2a data showing its IPF candidate GRI-0621 improved key clinical symptoms and ...